Innovative genomic-based model for personalized treatment of gastric cancer: Integrating current standards and new technologies

Expert Review of Molecular Diagnostics

Volumn 8, Issue 1, 2008, Pages 29-39

  Roukos, Dimitrios H ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Cancer stem cell; Gastric cancer; Gene signature; Individualized treatment; Network biology; Omics; Recurrence; Targeted therapy; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CISPLATIN; EPIRUBICIN; ERLOTINIB; FLAVOPIRIDOL; GEFITINIB; LAPATINIB; MARIMASTAT; MATUZUMAB; SORAFENIB; SUNITINIB; TRASTUZUMAB;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER STEM CELL; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; ENVIRONMENTAL FACTOR; GENE EXPRESSION; GENETIC ASSOCIATION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; KIDNEY CANCER; LYMPHADENECTOMY; MEDICAL DECISION MAKING; MUTATIONAL ANALYSIS; PROGNOSIS; REVIEW; STOMACH CANCER; TREATMENT PLANNING; ALGORITHM; GENETICS; GENOME; MUTATION; PATHOGENICITY; STOMACH TUMOR;

ALGORITHMS; GENOME, HUMAN; HELICOBACTER PYLORI; HUMANS; MUTATION; NEOPLASTIC STEM CELLS; STOMACH NEOPLASMS;

EID: 38149069029     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.8.1.29     Document Type: Review

References (92)

1. Roukos DH, Kappas AM. Perspectives in the treatment of gastric cancer. Nat. Clin. Pract. Oncol. 2, 98-107 (2005).
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55(2), 74-108 (2005).
3. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J. Clin. 56(2), 106-130 (2006).
4. Sano T. Tailoring treatments for curable gastric cancer. Br. J. Surg. 94(3), 263-264 (2007).
5. Sakuramoto S, Sasako M, Yamaguchi T et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N. Engl. J. Med. 357(18), 1810-1820 (2007).
6. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol. 24(14), 2137-2150 (2006).
7. Ozols RF, Herbst RS, Colson YL et al.; American Society of Clinical Oncology. Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening - a report from the American Society of Clinical Oncology. J. Clin. Oncol. 25(1), 146-162 (2007).
8. Taylor PR. Prevention of gastric cancer: a miss. J. Natl Cancer Inst. 99(2), 101-103 (2007).
9. Valverde CM, Macarulla T, Casado E, Ramos FJ, Martinelli E, Tabernero J. Novel targets in gastric and esophageal cancer. Crit. Rev. Oncol. Hematol. 59(2), 128-138 (2006).
10. Friedman A, Perrimon N. Genetic screening for signal transduction in the era of network biology. Cell 128(2), 225-231 (2007).
11. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat. Med. 10(8), 789-799 (2004).
12. Sjoblom T, Jones S, Wood LD. The consensus coding sequences of human breast and colorectal cancers. Science 314(5797), 268-274 (2006).
13. Bild AH, Potti A, Nevins JR. Linking oncogenic pathways with therapeutic opportunities. Nat. Rev. Cancer 6(9), 735-741 (2006).
14. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat. Rev. Cancer 7(6), 415-428 (2007).
15. Hendrix MJ, Seftor EA, Seftor RE et al. Reprogramming metastatic tumour cells with embryonic microenvironments. Nat. Rev. Cancer 7(4), 246-255 (2007).
16. Greenman C, Stephens P, Smith R et al. Patterns of somatic mutation in human cancer genomes. Nature 446(7132), 153-158 (2007).
17. + Helicobacter pylori infection and gastric cancer risk in the EPIC-EURGAST study. Int. J. Cancer 120(4), 859-867 (2007).
18. Thomas RK, Baker AC, Debiasi RM et al. High-throughput oncogene mutation profiling in human cancer. Nat. Genet. 39(3), 347-351 (2007).
19. Wood LD, Parsons DW, Jones S. The genomic landscapes of human breast and colorectal cancers. Science 318(5853), 1108-1113 (2007).
20. Green FL, Page DL, Fleming ID et al. (Eds). Esophagus. In: AJCC Cancer Staging Manual. 6th Edition. Springer-Verlag, NY, USA. 91-98 (2002).
21. Briasoulis E, Liakakos T, Dova L et al. Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev. Anticancer Ther. 6(6), 931-939 (2006).
22. Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat. Rev. Drug Discov. 6(4), 287-293 (2007).
23. Roukos DH, Murray S, Briasoulis E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol. Ther. 6(3), 308-312 (2007).
24. Roukos DH. HER2 and response to paclitaxel in node-positive breast cancer. N. Engl. J. Med. (In Press).
25. Roukos DH. Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N. Engl. J. Med. 357(15), 1555-1556; author reply 1556 (2007).
26. Ransohoff DF. Bias as a threat to the validity of cancer molecular-marker research. Nat. Rev. Cancer 5(2), 142-149 (2005).
27. Hinestrosa MC, Dickersin K, Klein P et al. Shaping the future of biomarker research in breast cancer to ensure clinical relevance. Nat. Rev. Cancer 7(4), 309-315 (2007).
28. Gutman S, Kessler LG. The US Food and Drug Administration perspective on cancer biomarker development. Nat. Rev. Cancer 6(7), 565-571 (2006).
29. Ioannidis JP. Is molecular profiling ready for use in clinical decision making? Oncologist 12(3), 301-311 (2007).
30. Sotiriou C, Piccart MJ. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat. Rev. Cancer 7(7), 545-553 (2007).
31. Wu CW, Hsiung SA, Lo et al. Nodal dissection for patients with gastric cancer: a randomised trial. Lancet Oncol. 7, 309-315 (2006).
32. Siewert JR, Bottcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg. 228(4), 449-461 (1998).
33. Sasako M. Principles of surgical treatment of curable gastric cancer. J. Clin. Oncol. 21, 274S-275S (2003).
34. Kappas AM, Fatouros M, Roukos DH. Is it time to change surgical strategy for gastric cancer in the United States? Ann. Surg. Oncol. 11(8), 727-730 (2004).
35. Roukos DH, Kappas AM. Targeting the optimal extent of lymph node dissection for gastric cancer. J. Surg. Oncol. 81(2), 59-62 (2002).
36. Macdonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med . 345, 725-730 (2001).
37. Roukos DH. Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann. Surg. Oncol. 9(3), 220-221 (2002).
38. Chabner BA, Roberts TG Jr. Timeline: chemotherapy and the war on cancer. Nat. Rev. Cancer 5(1), 65-72 (2005).
39. Panzini I, Gianni L, Fattori PP et al. Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori 88(1), 21-27 (2002).
40. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 355(1), 11-20 (2006).
41. Briasoulis E, Fatouros M, Roukos D. Level I evidence in support of perioperative chemotherapy for operable gastric cancer. Sufficient for wide clinical use? Ann. Surg. Oncol. 14(10), 2691-2695 (2007).
42. Schneider BP, Sledge GW Jr. Drug insight: VEGF as a therapeutic target for breast cancer. Nat. Clin. Pract. Oncol. 4(3), 181-189 (2007).
43. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 3(1), 24-40 (2006).
44. Hutchinson L. Targeted therapies: the answer to individualized treatment? Nat. Clin. Pract. Oncol. 4(6), 323 (2007).
45. Chua YJ, Cunningham D. The UK NCRI MAGIC Trial of Perioperative Chemotherapy in Resectable Gastric Cancer: implications for clinical practice. Ann. Surg. Oncol. 14(10), 2687-2690 (2007).
46. van de Vijver MJ, He YD, van't Veer LG et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347(25), 1999-2009 (2002).
47. Nashimoto A, Nakajima T, Furukawa H et al. Randomized trial of adjuvant chemotherapy with mitomycin, fluorouracil, and cytosine arabinoside followed by oral fluorouracil in serosanegative gastric cancer: Japan Clinical Oncology Group 9206-1. J. Clin. Oncol. 21(12), 2282-2287 (2003).
48. Roukos DH. Early-stage gastric cancer: a highly treatable disease. Ann. Surg. Oncol. 11(2), 127-129 (2004).
49. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol. Microbiol. Scand. 64, 31-49 (1965).
50. Kattan MW, Karpeh MS, Mazumdar M, Brennan MF. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J. Clin. Oncol. 21(19), 3647-3650 (2003).
51. Milne AN, Sitarz R, Carvalho R, Carneiro F, Offerhaus GJ. Early onset gastric cancer: on the road to unraveling gastric carcinogenesis. Curr. Mol. Med. 7(1), 15-28 (2007).
52. Hamilton JP, Meltzer SJ. A review of the genomics of gastric cancer. Clin. Gastroenterol. Hepatol. 4(4), 416-425 (2006).
53. Ziogas D, Baltogiannis, Fatouros M, Roukos DH. Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann. Surg. (In Press).
54. Roukos DH, Kappas AM, Tsianos E. Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann. Surg. Oncol. 9(7), 607-609 (2002).
55. Roukos DH, Briasoulis E. Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat. Clin. Pract. Oncol. 4, 578-590 (2007).
56. Roukos DH, Agnanti NJ, Paraskevaidis E, Kappas AM. Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann. Surg. Oncol. 9(10), 941-943 (2002).
57. Fatouros M, Baltoyiannis G, Roukos DH. The predominant role of surgery in the prevention and new trends in the surgical treatment of hereditary breast ovarian cancer. Ann. Surg. Oncol. (2007) (In Press).
58. Agnantis NJ, Paraskevaidis E, Roukos D. Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann. Surg. Oncol. 11(12), 1030-1034 (2004).
59. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat. Med. 12, 695-904 (2006).
60. Christofori G. Division of labour. Nature 446, 735-736 (2007).
61. Gupta GP, Nguyen DX, Chiang AC et al. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 446(7137), 765-770 (2007).
62. van't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002).
63. Buyse M, Loi S, van't Veer L et al. Validation and clinical utility of a 70-gene prognostic signature for women with node negative breast cancer. J. Natl Cancer Inst. 98, 1183-1192 (2006).
64. Wang Y, Klijn JG, Zhang Y et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365(9460), 671-679 (2005).
65. Foekens JA, Atkins D, Zhang Y et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J. Clin. Oncol. 24(11), 1665-1671 (2006).
66. Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24, 3726-3734 (2006).
67. Sims AH, Ong KR, Clarke RB, Howell A. High-throughput genomic technology in research and clinical management of breast cancer. Exploiting the potential of gene expression profiling: is it ready for the clinic? Breast Cancer Res. 8(5), 214 (2006).
68. Desmedt C, Piette F, Loi S et al. Strong time-dependency of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multi-centre independent validation series. Clin. Cancer Res.13, 3207-3214 (2007).
69. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J. Clin. Invest. 115(6), 1503-1521 (2005).
70. Liu R, Wang X, Chen GY et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N. Engl. J. Med. 356(3), 217-226 (2007).
71. Chen HY, Yu SL, Chen CH et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N. Engl. J. Med. 356(1), 11-20 (2007).
72. Potti A, Mukherjee S, Petersen R et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N. Engl. J. Med . 355(6), 570-580 (2006).
73. Barrier A, Boelle PY, Roser F et al. Stage II colon cancer prognosis prediction by tumor gene expression profiling. J. Clin. Oncol. 24(29), 4685-4691 (2006).
74. Del Rio M, Molina F, Bascoul-Mollevi C et al. Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J. Clin. Oncol. 25(7), 773-780 (2007).
75. Ramaswamy S, Golub TR. DNA microarrays in clinical oncology. J. Clin. Oncol. 20(7), 1932-1941 (2002).
76. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 8(2), 98-101 (1989).
77. Moore KA, Lemischka IR. Stem cells and their niches. Science 311(5769), 1880-1885 (2006).
78. Clarke MF, Fuller M. Stem cells and cancer: two faces of eve. Cell 124(6), 1111-1115 (2006).
79. Sawyers CL. Calculated resistance in cancer. Nat. Med. 11(8), 824-845 (2005).
80. Hunter DJ, Kraft P. Drinking from the fire hose - statistical issues in genomewide association studies. N. Engl. J. Med . 357(5), 436-439 (2007).
81. ENCODE Project Consortium; Birney E, Stamatoyannopoulos JA, Dutta A et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447(7146), 799-816 (2007).
82. Papadopoulos N, Kinzler KW, Vogelstein B. The role of companion diagnostics in the development and use of mutation-targeted cancer therapies. Nat. Biotechnol. 24(8), 985-995 (2006).
83. Kuramitsu Y, Nakamura K. Proteomic analysis of cancer tissues: shedding light on carcinogenesis and possible biomarkers. Proteomics 6(20), 5650-5661 (2006).
84. Claudino WM, Quattrone A, Biganzoli L, Pestrin M, Bertini I, Di Leo A. Metabolomics: available results, current research projects in breast cancer, and future applications. J. Clin. Oncol. 25(19), 2840-2846 (2007).
85. Thomas DC, Clayton DG. Betting odds and genetic associations. J. Cancer Inst. 96(6), 421-423 (2004).
86. Segal E, Friedman N, Kaminski N, Regev A, Koller D. From signatures to models: understanding cancer using microarrays. Nat. Genet. 37(Suppl.) S38-S45 (2005).
87. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100(1), 57-70 (2000).
88. Katoh Y, Katoh M. Hedgehog signaling pathway and gastrointestinal stem cell signaling network. Int. J. Mol. Med. 18(6), 1019-1023 (2006).
89. Houghton J, Stoicov C, Nomura S et al. Gastric cancer originating from bone marrow-derived cells. Science 306(5701), 1568-1571 (2004).
90. Whitehurst AW, Bodemann BO, Cardenas J et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 446(7137), 815-819 (2007).
91. Roukos DH, Lorenz M, Karakostas K, Paraschou P, Batsis C, Kappas AM. Pathological serosa and node-based classification accurately predicts gastric cancer recurrence risk and outcome, and determines potential and limitation of a Japanese-style extensive surgery for Western patients: a prospective with quality control 10-year follow-up study. Br. J. Cancer 84(12), 1602-1609 (2001).
92. Minn AJ, Gupta GP, Padua D et al. Lung metastasis genes couple breast tumor size and metastatic spread. Proc. Natl Acad. Sci. USA 104(16), 6740-6745 (2007).